共 321 条
[1]
Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer. 136 E359-E386
[2]
Soerjomataram I(2018)Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance Oncologist. 23 528-539
[3]
Dikshit R(2014)Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer Endocr Relat Cancer. 21 R235-R246
[4]
Eser S(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816
[5]
Mathers C(2011)Mechanisms of endocrine resistance in breast cancer Annu Rev Med. 62 233-247
[6]
Rebelo M(2012)The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin Breast Cancer Res Treat. 133 459-471
[7]
Brufsky AM(2008)Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response Clin Cancer Res. 14 5555-5564
[8]
Dickler MN(2013)Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer Hum Pathol. 44 2028-2037
[9]
Jordan VC(2013)Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate Breast Cancer Res Treat. 142 537-548
[10]
Davies C(2011)Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen Future Oncol. 7 995-1006